Metabolic correction in microglia derived from Sandhoff disease model mice.
Sandhoff disease is an autosomal recessive lysosomal storage disease caused by a defect of the beta-subunit gene (HEXB) associated with simultaneous deficiencies of beta-hexosaminidase A (HexA; alphabeta) and B (HexB; betabeta), and excessive accumulation of GM2 ganglioside (GM2) and oligosaccharides with N-acetylglucosamine (GlcNAc) residues at their non-reducing termini. Recent studies have shown the involvement of microglial activation in neuroinflammation and neurodegeneration of this disease. We isolated primary microglial cells from the neonatal brains of Sandhoff disease model mice (SD mice) produced by disruption of the murine Hex beta-subunit gene allele (Hexb-/-). The cells expressed microglial cell-specific ionized calcium binding adaptor molecule 1 (Iba1)-immunoreactivity (IR) and antigen recognized by Ricinus communis agglutinin lectin-120 (RCA120), but not glial fibrillary acidic protein (GFAP)-IR specific for astrocytes. They also demonstrated significant intracellular accumulation of GM2 and GlcNAc-oligosaccharides. We produced a lentiviral vector encoding for the murine Hex beta-subunit and transduced it into the microglia from SD mice with the recombinant lentivirus, causing elimination of the intracellularly accumulated GM2 and GlcNAc-oligosaccharides and secretion of Hex isozyme activities from the transduced SD microglial cells. Recomibinant HexA isozyme isolated from the conditioned medium of a Chinese hamster ovary (CHO) cell line simultaneously expressing the human HEXA (alpha-subunit) and HEXB genes was also found to be incorporated into the SD microglia via cell surface cation-independent mannose 6-phosphate receptor and mannose receptor to degrade the intracellularly accumulated GM2 and GlcNAc-oligosaccharides. These results suggest the therapeutic potential of recombinant lentivirus encoding the murine Hex beta-subunit and the human HexA isozyme (alphabeta heterodimer) for metabolic cross-correction in microglial cells involved in progressive neurodegeneration in SD mice.
Tsuji
Daisuke
D
Department of Medicinal Biotechnology, Institute for Medicinal Resources, Graduate School of Pharmaceutical Sciences, The University of Tokushima, 178 Sho-machi, Tokushima, Japan.
Kuroki
Aya
A
Ishibashi
Yasuhiro
Y
Itakura
Tomohiro
T
Itoh
Kohji
K
D000818:Animals; D001921:Brain / Q000378:metabolism* / Q000503:physiopathology / Q000821:virology; D002135:Calcium-Binding Proteins / Q000378:metabolism; D019281:Dimerization; D004195:Disease Models, Animal; D004660:Encephalitis / Q000235:genetics / Q000378:metabolism* / Q000503:physiopathology; D005260:Female; D005678:G(M2) Ganglioside / Q000378:metabolism; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors / Q000235:genetics / Q000627:therapeutic use; D005911:Gliosis / Q000235:genetics / Q000378:metabolism* / Q000503:physiopathology; D054818:Hexosaminidase A; D054819:Hexosaminidase B; D006801:Humans; D007527:Isoenzymes / Q000235:genetics; D016086:Lentivirus / Q000235:genetics / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008840:Microfilament Proteins; D017628:Microglia / Q000378:metabolism*; D021122:Protein Subunits / Q000235:genetics; D017527:Receptor, IGF Type 2 / Q000378:metabolism; D012497:Sandhoff Disease / Q000235:genetics / Q000378:metabolism* / Q000628:therapy; D001619:beta-N-Acetylhexosaminidases / Q000235:genetics*
C491049:Aif1 protein, mouse; D002135:Calcium-Binding Proteins; D007527:Isoenzymes; D008840:Microfilament Proteins; D021122:Protein Subunits; D017527:Receptor, IGF Type 2; D005678:G(M2) Ganglioside; D054818:Hexosaminidase A; D054819:Hexosaminidase B; D001619:beta-N-Acetylhexosaminidases